Literature DB >> 31640951

[Association of adenylate cyclase-associated protein 2 expression with histopathology and long-term prognosis of gastric cancer].

Sitang Ge1, Shan Wang1, Wujun Xiang1, Lili Wang1, Yuke Zhu1, Xiang Zhu2, Xun Wang2, Lugen Zuo2, Congqiao Jiang1, Siqing Li1, Mulin Liu1.   

Abstract

OBJECTIVE: To explore association of the expression levels of adenylate cyclase-associated protein 2 (CAP2) in gastric cancer tissues with the histopathology and long-term prognosis of the malignancy.
METHODS: This study was conducted among a total of 105 patients with gastric cancer undergoing radical gastrectomy in our hospital between January, 2010 and October, 2013. Immunohistochemistry was used to quantitatively assess the expression of CAP2 in gastric cancer tissues and the adjacent tissues. Based on the median relative expression level of CAP2 of 3.5, the patients were divided into low CAP2 expression group (n=52) and high CAP2 expression group (n=53). The Cox regression model was used to analyze the effect of CAP2 expression on the 5-year survival rate of the patients, and ROC curve analysis was used to assess the predictive value of CAP2 expression for the patients' long-term survival.
RESULTS: Immunohistochemical analysis showed that the expression levels of CAP2 (P < 0.01) and Ki67 (P < 0.01) were significantly higher in gastric cancer tissues than in the adjacent tissues, and the expression level of CAP2 was positively correlated with Ki67 (P < 0.01), peripheral blood CEA (P < 0.01) and CA19-9 (P < 0.01). The percentages of patients with CEA≥5 μg/L, CA19-9≥37 kU/L, pathological grade of G3-G4, T stage of 3-4, and N stage of 2-3 were significantly higher in patients with high CAP2 expression than in those with low CAP2 expression (P < 0.05). Kaplan- Meier survival analysis showed that the 5-year survival rate was significantly lower in patients with a high CAP2 expression (P < 0.01). A high expression level of CAP2, CEA≥5μg/L, CA19-9≥37 and pathological grades G3-G4 were all independent risk factors for shortened 5-year survival after radical gastrectomy (P < 0.01). With the relative expression level of 3.45 as the cut-off value, the sensitivity of CAP2 was 70.15% for predicting death 5 years after the surgery, with a specificity of 71.05% and an area under the curve of 0.779 (P < 0.01).
CONCLUSIONS: CAP2 is highly expressed in gastric cancer tissues in close relation with the tumor progression. CAP2 is an independent risk factor for 5-year survival rate after radical gastrectomy for gastric cancer and can be of clinical value in prognostic evaluation of the patients.

Entities:  

Keywords:  adenylate cyclase-associated protein 2; gastric cancer; pathology; risk factor analysis; survival analysis

Mesh:

Substances:

Year:  2019        PMID: 31640951      PMCID: PMC6881740          DOI: 10.12122/j.issn.1673-4254.2019.09.08

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  27 in total

1.  7th edition of the AJCC cancer staging manual: stomach.

Authors:  Kay Washington
Journal:  Ann Surg Oncol       Date:  2010-12       Impact factor: 5.344

Review 2.  Gastric cancer treatment in the world: Germany.

Authors:  Seung-Hun Chon; Felix Berlth; Patrick Sven Plum; Till Herbold; Hakan Alakus; Robert Kleinert; Stefan Paul Moenig; Christiane Josephine Bruns; Arnulf Heinrich Hoelscher; Hans-Joachim Meyer
Journal:  Transl Gastroenterol Hepatol       Date:  2017-05-26

Review 3.  Genetic variants in gastric cancer: Risks and clinical implications.

Authors:  Carolina Oliveira Gigek; Danielle Queiroz Calcagno; Lucas Trevizani Rasmussen; Leonardo Caires Santos; Mariana Ferreira Leal; Fernanda Wisnieski; Rommel Rodriguez Burbano; Laercio Gomes Lourenço; Gaspar Jesus Lopes-Filho; Marilia Arruda Cardoso Smith
Journal:  Exp Mol Pathol       Date:  2017-07-20       Impact factor: 3.362

4.  Induction of Pro-Inflammatory Response via Activated Macrophage-Mediated NF-κB and STAT3 Pathways in Gastric Cancer Cells.

Authors:  Yujuan Zhou; Longzheng Xia; Qiang Liu; Heran Wang; Jingguan Lin; Linda Oyang; Xiaoyan Chen; Xia Luo; Shiming Tan; Yutong Tian; Min Su; Ying Wang; Pan Chen; Yang Wu; Hui Wang; Qianjin Liao
Journal:  Cell Physiol Biochem       Date:  2018-06-19

5.  CAP2 is a regulator of the actin cytoskeleton and its absence changes infiltration of inflammatory cells and contraction of wounds.

Authors:  Kosmas Kosmas; Ali Eskandarnaz; Arya B Khorsandi; Atul Kumar; Rajeev Ranjan; Sabine A Eming; Angelika A Noegel; Vivek S Peche
Journal:  Eur J Cell Biol       Date:  2014-11-03       Impact factor: 4.492

6.  Expression status of cyclase‑associated protein 2 as a prognostic marker for human breast cancer.

Authors:  Lihua Xu; Sida Peng; Qunai Huang; Yu Liu; Hua Jiang; Xi Li; Jiani Wang
Journal:  Oncol Rep       Date:  2016-08-25       Impact factor: 3.906

7.  Ablation of cyclase-associated protein 2 (CAP2) leads to cardiomyopathy.

Authors:  Vivek S Peche; Tad A Holak; Bhagyashri D Burgute; Kosmas Kosmas; Sushant P Kale; F Thomas Wunderlich; Fatiha Elhamine; Robert Stehle; Gabriele Pfitzer; Klaus Nohroudi; Klaus Addicks; Florian Stöckigt; Jan W Schrickel; Julia Gallinger; Michael Schleicher; Angelika A Noegel
Journal:  Cell Mol Life Sci       Date:  2012-09-04       Impact factor: 9.261

8.  Clinical Impact of the Location of Lymph Node Metastases After Neoadjuvant Chemotherapy for Middle and Lower Thoracic Esophageal Cancer.

Authors:  Hiroshi Miyata; Keijirou Sugimura; Makoto Yamasaki; Tomoki Makino; Koji Tanaka; Eiichi Morii; Takeshi Omori; Kazuyoshi Yamamoto; Yoshitomo Yanagimoto; Masahiko Yano; Shinichi Nakatsuka; Masaki Mori; Yuichiro Doki
Journal:  Ann Surg Oncol       Date:  2018-10-29       Impact factor: 5.344

Review 9.  Low lymphocyte count and high monocyte count predicts poor prognosis of gastric cancer.

Authors:  Fan Feng; Gaozan Zheng; Qiao Wang; Shushang Liu; Zhen Liu; Guanghui Xu; Fei Wang; Man Guo; Xiao Lian; Hongwei Zhang
Journal:  BMC Gastroenterol       Date:  2018-10-11       Impact factor: 3.067

Review 10.  Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer.

Authors:  Daniela Cornelia Lazăr; Mihaela Flavia Avram; Ioan Romoșan; Mărioara Cornianu; Sorina Tăban; Adrian Goldiș
Journal:  World J Gastroenterol       Date:  2018-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.